A retrospective analysis of clinical characteristics and prognostic factors for primary breast diffuse large B cell lymphoma
10.13315/j.cnki.cjcep.2018.03.005
- VernacularTitle:原发性乳腺弥漫大B细胞淋巴瘤的临床病理特征及预后
- Author:
Xiu ZHU
1
;
Wen-Juan YIN
;
Mei-Juan WU
;
Guo-Ping CHENG
;
Wen-Yong SUN
;
Xing-Hao NI
Author Information
1. 浙江省肿瘤医院病理科
- Keywords:
lymphoma;
diffuse large B cell lymphoma;
immunohistochemistry;
clinical characteristics
- From:
Chinese Journal of Clinical and Experimental Pathology
2018;34(3):257-262
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To study the clinical features, immunophenotypes and prognostic factors of primary breast diffuse large B-celllymphoma (PBDLBCL). Methods The clinical pathological data of 49 cases of PBDLBCL during January 2006 to December 2016 were retrospectively analysed, and the basic clinical and pathologic data, pathologic types and the immunohistochemical slides by EnVision method for staining were summarized. Results 47 cases were women and 2 cases were men. The age ranged from 24 to 79 year old with the median age of 48 year old. On microscopic observation, tumor cells were large to medium-sized which characterized as diffuse infiltration between the lobules of mammary gland, around the duct, interstitial and fat tissue, some were single file cord pattern. The immunophenotype showed 37 cases were of non-GCB, 12 cases were GCB type. Ki-67 index were greater than 40％. According to Ann Arbor staging, 16 cases were stage I EA, 28 cases were stage Ⅱ EA, 5 cases were stage Ⅳ E. IPI score: 30 cases with 0 ～1 score, 10 cases with 2 score, 9 cases with 3 score. Patients were followed up from 5 to 146 months, The 3-year overall survival (OS) rate was 51.2％ and 5-year OS rate was 36.7％, Single factor analysis showed that there were statistically significant difference in clinical stage, levels of LDH, IPI score, BCL-2 protein expression, and BCL-6 protein expression in 3 and 5 years of OS rate. The multiple factor analysis of Cox regression showed that the increase of IPI risk classification was the independent adverse prognostic factor of primary breast diffuse large B-cell lymphoma. Conclusion The diagnosis of PBDLBCL is confirmed by pathological biopsy and immunohistochemical markers. The immunophenotype was mainly non-GCB type. Comprehensive treatment including surgery, chemotherapy and radiotherapy is appropriate. The prognosis should be comprehensively evaluated by multiple factors. IPI increase risk classification is the independent adverse prognostic factor.
